Accuray Pushes AI-Driven Radiation Therapy Amid Global Expansion

TL;DR

**ARAY is a speculative buy, betting on its AI-driven radiation therapy innovation and aggressive global expansion to carve out a niche in a competitive market.**

AI Summary

Accuray Inc. (ARAY) filed its 10-K for the fiscal year ended June 30, 2025, highlighting its focus on advanced radiation therapy systems like the CyberKnife and Radixact platforms. The company emphasizes its AI-driven solutions for adaptive treatment delivery, aiming to enhance precision and reduce treatment times. Key strategic initiatives include increasing physician adoption and patient awareness, expanding the radiosurgery market, and fostering innovation through clinical development and collaborations. Accuray is also aggressively pursuing international market expansion, with regional offices in Switzerland, China, and Japan, and direct sales staff in Western Europe, Japan, India, and Canada. Strategic partnerships, such as those with GE Healthcare and Airbus SAS, are central to its growth, focusing on personalized cancer care and AI-driven performance prediction. The company reported an aggregate market value of common stock held by non-affiliates of $146,769,044 as of December 31, 2024, with 112,677,147 shares outstanding as of August 22, 2025.

Why It Matters

Accuray's advancements in AI-driven radiation therapy, particularly with its CyberKnife and Radixact systems, could significantly impact cancer treatment paradigms, offering more precise and efficient options for patients. For investors, this signals potential for market share growth in a competitive medical device landscape dominated by larger players like Varian Medical Systems (now Siemens Healthineers) and Elekta. Employees benefit from working on cutting-edge technology, while customers (hospitals and clinics) gain tools to improve patient outcomes and operational efficiency. The broader market could see a shift towards more personalized and adaptive radiotherapy, driven by Accuray's strategic partnerships and international expansion efforts.

Risk Assessment

Risk Level: medium — The company operates in a highly competitive and regulated medical device market, facing risks from larger, more established competitors. Its reliance on strategic partnerships and international expansion, particularly in less developed regions, introduces execution risks. The 10-K also highlights the impact of macroeconomic conditions, inflation, and supply chain issues on operations and financial results, indicating potential volatility.

Analyst Insight

Investors should monitor Accuray's progress in securing new partnerships and expanding its international footprint, particularly the success of its Accuray Helix system in addressing patient access gaps. Evaluate quarterly reports for specific revenue growth from new product adoptions and geographic expansion, as these will be key indicators of its ability to execute its strategy and mitigate competitive pressures.

Financial Highlights

debt To Equity

X.X

revenue

$146.8M

operating Margin

X%

total Assets

$X

total Debt

$X

net Income

$X

eps

$X

gross Margin

X%

cash Position

$X

revenue Growth

+X%

Key Numbers

• $146.8M — Market Value of Non-Affiliate Common Stock (As of December 31, 2024, indicating market capitalization for public float.)
• 112.7M — Outstanding Shares (As of August 22, 2025, representing the total shares available.)
• 1990 — Incorporation Year (Company was incorporated in California, showing its long operational history.)
• 2007 — Reincorporation Year (Company reincorporated in Delaware, a common move for corporate governance.)
• 15 minutes — CyberKnife S7 Treatment Time (Minimum treatment time for SRS and SBRT, highlighting efficiency improvements.)

Key Players & Entities

• ACCURAY INCORPORATED (company) — Registrant
• CyberKnife (company) — Product platform
• TomoTherapy (company) — Product platform
• Radixact System (company) — Next generation TomoTherapy platform
• CNNC High Energy Equipment (Tianjin) Co., Ltd. (company) — Joint venture partner
• GE Healthcare (company) — Global commercial partner
• Airbus SAS (company) — Collaboration partner for AI-driven solution
• RaySearch Laboratories AB (company) — Treatment planning support partner
• Brainlab (company) — Collaboration partner for neuro-radiosurgery
• $146,769,044 (dollar_amount) — Aggregate market value of common stock held by non-affiliates as of December 31, 2024

FAQ

Risk Factors

• Competition from established and emerging players [high — market]: The radiation therapy market is highly competitive, with established players like Varian Medical Systems and Elekta, as well as emerging companies. Accuray faces risks if competitors develop superior technologies or offer more competitive pricing, potentially impacting market share and revenue. The company's success depends on its ability to differentiate its CyberKnife and Radixact platforms through innovation and clinical evidence.
• Regulatory approvals and compliance [high — regulatory]: Accuray's products require stringent regulatory approvals from bodies like the FDA in the U.S. and CE marking in Europe. Delays or failures in obtaining these approvals for new products or features can hinder market entry and revenue generation. Ongoing compliance with evolving regulatory standards is critical and resource-intensive.
• Supply chain disruptions and manufacturing challenges [medium — operational]: The company relies on a complex global supply chain for its advanced radiation therapy systems. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact production schedules and the ability to meet customer demand. Manufacturing complex medical devices also carries inherent risks of quality control issues.
• Dependence on capital expenditures by healthcare providers [medium — financial]: Accuray's sales are heavily influenced by the capital expenditure budgets of hospitals and cancer treatment centers. Economic downturns or shifts in healthcare reimbursement policies can lead to reduced spending on new equipment, impacting Accuray's revenue and order pipeline. The company's ability to secure financing for customers can also be a factor.
• Technological obsolescence and innovation pace [high — market]: The medical technology landscape evolves rapidly. Accuray must continuously invest in research and development to keep its CyberKnife and Radixact platforms competitive. Failure to innovate at a pace that matches or exceeds competitors could lead to its technologies becoming obsolete, impacting future sales and market position.
• Reliance on key personnel and skilled workforce [medium — operational]: The development, manufacturing, sales, and support of advanced radiation therapy systems require highly specialized expertise. The loss of key scientific, engineering, or sales personnel, or an inability to attract and retain a skilled workforce, could negatively impact the company's operations and growth initiatives.
• Product liability and intellectual property disputes [medium — legal]: As a manufacturer of complex medical devices, Accuray is exposed to potential product liability claims. Litigation related to product performance or alleged defects could result in significant financial liabilities and reputational damage. Disputes over intellectual property rights could also arise.
• International market expansion risks [medium — financial]: While international expansion is a strategic focus, it introduces risks related to currency fluctuations, varying regulatory environments, political instability, and challenges in establishing effective distribution and support networks in diverse markets like China and Japan. Economic conditions in these regions can also impact demand.

Industry Context

Accuray operates in the highly specialized medical device market for radiation therapy. The industry is characterized by significant R&D investment, long sales cycles, and stringent regulatory oversight. Key trends include the increasing adoption of AI for treatment planning and delivery, demand for more personalized and adaptive treatment approaches, and a growing focus on improving efficiency and reducing treatment times. Competitors include established players like Varian Medical Systems and Elekta, as well as emerging technology providers.

Regulatory Implications

Accuray's business is heavily influenced by regulatory bodies such as the FDA and international equivalents. Obtaining and maintaining regulatory clearance for its advanced systems (CyberKnife, Radixact) is critical for market access. Evolving regulations around data privacy (e.g., HIPAA) and cybersecurity for medical devices also present compliance challenges and require ongoing investment.

What Investors Should Do

1. Monitor international revenue growth
2. Assess adoption of AI-driven solutions
3. Evaluate competitive positioning
4. Analyze R&D investment and pipeline
5. Track order backlog and capital expenditure trends

Key Dates

• 2025-06-30: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, encompassing financial performance and operational highlights for the year.
• 2024-12-31: Market Value of Non-Affiliate Common Stock Calculation — Provides a snapshot of the public float's market capitalization, indicating investor valuation as of a specific date.
• 2025-08-22: Outstanding Shares Calculation — Confirms the total number of shares outstanding, crucial for per-share metric calculations and understanding equity structure.
• 1990-XX-XX: Company Incorporation — Indicates the company's founding year, highlighting its long-standing presence in the radiation therapy market.
• 2007-XX-XX: Company Reincorporation — Marks a significant corporate governance change, often to a more business-friendly jurisdiction like Delaware.

Glossary

CyberKnife

Accuray's robotic, image-guided stereotactic radiosurgery and stereotactic body radiation therapy system. (A core product line, central to the company's advanced treatment delivery capabilities and market strategy.)

Radixact System

Accuray's next-generation TomoTherapy platform, designed for precision and efficiency in radiation therapy. (Represents the evolution of their TomoTherapy technology, crucial for maintaining a competitive edge in the market.)

Stereotactic Radiosurgery (SRS)

A type of radiation therapy that uses precisely focused beams of radiation to treat tumors and other abnormalities in the brain and body. (A key treatment modality offered by Accuray's systems, indicating the precision and advanced nature of their technology.)

Stereotactic Body Radiation Therapy (SBRT)

Similar to SRS but used for tumors outside the brain, delivering high doses of radiation to small areas of the body over a few treatment sessions. (Another critical application for Accuray's platforms, highlighting their versatility in treating various complex cancer cases.)

Intensity Modulated Radiation Therapy (IMRT)

An advanced form of radiation therapy that uses computer-controlled X-ray beams to precisely target cancer cells while minimizing damage to surrounding healthy tissue. (A standard but advanced treatment technique that Accuray's systems are designed to deliver with high precision.)

Image-Guided Radiation Therapy (IGRT)

The use of imaging during radiation therapy to verify the position of the tumor and ensure accurate radiation delivery. (Essential for Accuray's systems, enabling real-time adjustments and enhancing treatment accuracy, especially for moving targets.)

Adaptive Radiation Therapy (ART)

A type of radiation therapy where the treatment plan is adjusted during the course of treatment based on changes in the tumor size, shape, or position, or changes in the patient's anatomy. (A key focus for Accuray, particularly with their AI-driven solutions, aiming to improve treatment efficacy by adapting to patient-specific changes.)

Deep Inspiration Breath Hold (DIBH)

A technique used in radiation therapy, particularly for breast cancer, where the patient holds their breath at a specific point during deep inspiration to move the breast away from the heart and lungs, reducing radiation dose to these organs. (Highlights a specific advanced capability of Accuray's systems, demonstrating their ability to handle complex patient positioning and organ motion for precise treatments.)

Year-Over-Year Comparison

The 10-K filing for the fiscal year ended June 30, 2025, will likely show continued efforts by Accuray to grow revenue through international expansion and the adoption of its advanced CyberKnife and Radixact platforms, particularly those incorporating AI for adaptive treatments. Investors will be looking for year-over-year revenue growth, improvements in gross margins reflecting potential economies of scale or pricing power, and changes in operating expenses related to R&D and sales & marketing. New risk factors may emerge related to evolving cybersecurity threats or geopolitical impacts on international markets, while existing risks like competition and regulatory hurdles remain prominent.

Key Financial Figures

• $0.001 — nge on Which Registered Common Stock, $0.001 par value per share ARAY The Nasdaq

Filing Documents

• aray-20250630.htm (10-K) — 4638KB
• aray-ex10_30.htm (EX-10.30) — 25KB
• aray-ex10_34.htm (EX-10.34) — 1799KB
• aray-ex19_1.htm (EX-19.1) — 118KB
• aray-ex21_1.htm (EX-21.1) — 23KB
• aray-ex23_1.htm (EX-23.1) — 5KB
• aray-ex31_1.htm (EX-31.1) — 15KB
• aray-ex31_2.htm (EX-31.2) — 14KB
• aray-ex32_1.htm (EX-32.1) — 10KB
• aray-ex97_1.htm (EX-97.1) — 51KB
• 0001193125-25-191242.txt ( ) — 22073KB
• aray-20250630.xsd (EX-101.SCH) — 2590KB
• aray-20250630_htm.xml (XML) — 4153KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 27 Item 1B. Unresolved Staff Comments 66 Item 1C. Cybersecurity 66 Item 2.

Properties

Properties 68 Item 3.

Legal Proceedings

Legal Proceedings 68 Item 4. Mine Safety Disclosures 68 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 69 Item 6. [RESERVED] 69 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 69 Item 7A. Quantitative and Qualitative Disclosure About Market Risk 80 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 82 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 125 Item 9A.

Controls and Procedures

Controls and Procedures 125 Item 9B. Other Information 126 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 126 PART III Item 10. Directors, Executive Officers and Corporate Governance 128 Item 11.

Executive Compensation

Executive Compensation 128 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 128 Item 13. Certain Relationships and Related Transactions, and Director Independence 128 Item 14. Principal Accountant Fees and Services 128 PART IV Item 15. Exhibits and Financial Statement Schedules 129 Item 16. Form 10-K Summary 132

Signatures

Signatures 133 We own or have rights to various trademarks and tradenames used in our business in the United States or other countries, including the following: Accuray , Accuray Logo , CyberKnife , HiArt , RoboCouch , Synchrony , TomoTherapy , Xsight , Accuray Precision , AutoSegmentation, CTrue, H Series, iDMS , InCise, Iris, CyberKnife M6 Series, Accuray OIS Connect, PreciseART , PreciseRTX , Treatment Planning System, TomoDirect, TomoEDGE, TomoH , TomoHD , TomoHDA, TomoHelical, TomoTherapy Quality Assurance, Radixact , Onrad , S7, Accuray Helix, CyberComm, AEX , ClearRT , XChange , and VoLO. 2 Table of Contents SPECIAL NOTE REGARDING FORWARDLOOKING STATEMENTS This Annual Report on Form 10K includes forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements regarding expectations and beliefs regarding the effect of macroeconomic conditions, inflation and changes in government administration policy positions as a result of the current presidential administration on our operations and financial results as well as the markets and industry in general; future revenues and expenses, including our expectations regarding timing of recognition of revenue from performance obligations and our expectations regarding the impact of supply chain issues; our sales, distribution and marketing efforts; reimbursement rates and its effects on our business; regulatory requirements, including our compliance with applicable regulations; future orders and expectations regarding our book-to-bill ratio; the radiation therapy market; expectations regarding the economic impact of cancer; our strategy; our products and offerings, including their capabilities and benefits and anticipated benefits to patients and physicians; the factors that contribute to the long-term success of our products; our suppliers and manufacturing facil

BUSINESS

Item 1. BUSINESS The Company Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases even more straightforward, to meet the full spectrum of patient needs. We believe in comparison to conventional linear accelerators, our treatment delivery, planning, and data management solutions provide better accuracy, flexibility, and control; fewer treatments with shorter treatment times; and the technology to expand beyond cancer, making it easier for clinical teams around the world to provide treatments that help patients get back to living their lives, faster. Our solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Our solutions include: Novel artificial intelligence ("AI") driven radiation therapy systems that automatically adapt treatment delivery for targets that move, synchronizing the radiation beam with the target's motion in real-time throughout treatment delivery. Powerful treatment planning software that reduces the time to create high quality treatment plans and the time it takes to deliver patient treatments as compared to the prior planning software, so clinicians can treat more patients each day. One-of-a-kind imaging solution designed to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively. Automated tools that help to identify the interfraction changes for which re-planning is clinically beneficial and facilitate adaptation of the radiation dose to precisely conform to the patient's tumor. Distinctive software that accelerates and automates the re-planning process to make re-treatment of a previously irradiated area more efficient for practices and more effective for patient

View Full Filing

View this 10-K filing on SEC EDGAR